Connor Clark & Lunn Investment Management Ltd. Buys 31,689 Shares of Haemonetics Co. (NYSE:HAE)

Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 14.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 252,142 shares of the medical instruments supplier's stock after purchasing an additional 31,689 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.50% of Haemonetics worth $19,687,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Parkside Financial Bank & Trust grew its position in Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after purchasing an additional 240 shares in the last quarter. AlphaQuest LLC boosted its stake in Haemonetics by 36,520.0% in the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after purchasing an additional 1,826 shares during the period. KBC Group NV grew its position in Haemonetics by 54.6% during the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after buying an additional 712 shares in the last quarter. iSAM Funds UK Ltd purchased a new position in Haemonetics in the third quarter worth $204,000. Finally, HighTower Advisors LLC boosted its stake in Haemonetics by 7.8% in the fourth quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock worth $262,000 after buying an additional 244 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Remove Ads

Haemonetics Price Performance

Shares of HAE traded down $0.69 during trading hours on Monday, reaching $64.84. 1,156,551 shares of the stock traded hands, compared to its average volume of 647,098. The company has a market cap of $3.26 billion, a P/E ratio of 25.53, a price-to-earnings-growth ratio of 1.11 and a beta of 0.43. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The company's 50-day moving average price is $68.61 and its two-hundred day moving average price is $75.41. Haemonetics Co. has a 52-week low of $58.80 and a 52-week high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current year.

Analysts Set New Price Targets

HAE has been the subject of a number of research analyst reports. Bank of America lowered Haemonetics from a "neutral" rating to an "underperform" rating and dropped their price target for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. Barrington Research cut their price target on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. JMP Securities decreased their price objective on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a report on Friday, February 7th. JPMorgan Chase & Co. began coverage on Haemonetics in a research note on Friday, December 6th. They set an "overweight" rating and a $116.00 target price on the stock. Finally, Needham & Company LLC lowered their price target on Haemonetics from $112.00 to $108.00 and set a "buy" rating on the stock in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $101.67.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.